Transcriptional Mechanisms of Resistance to Anti-PD-1 Therapy

被引:65
作者
Ascierto, Maria L. [1 ,2 ]
Makohon-Moore, Alvin [3 ,4 ]
Lipson, Evan J. [1 ,2 ]
Taube, Janis M. [2 ,5 ,6 ]
McMiller, Tracee L. [2 ,7 ]
Berger, Alan E. [2 ,8 ]
Fan, Jinshui [2 ,8 ]
Kaunitz, Genevieve J. [2 ,5 ]
Cottrell, Tricia R. [2 ,6 ]
Kohutek, Zachary A. [9 ]
Favorov, Alexander [2 ,10 ,11 ]
Makarov, Vladimir [4 ,9 ]
Riaz, Nadeem [4 ,9 ]
Chan, Timothy A. [4 ,9 ]
Cope, Leslie [2 ,10 ]
Hruban, Ralph H. [2 ,6 ,12 ]
Pardoll, Drew M. [1 ,2 ]
Taylor, Barry S. [4 ,13 ,14 ]
Solit, David B. [14 ]
Iacobuzio-Donahue, Christine A. [3 ,4 ]
Topalian, Suzanne L. [2 ,7 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA
[2] Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[3] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA
[5] Johns Hopkins Univ, Sch Med, Dept Dermatol, Baltimore, MD 21205 USA
[6] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA
[7] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA
[8] Johns Hopkins Univ, Sch Med, Lowe Family Genom Core, Baltimore, MD USA
[9] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 York Ave, New York, NY 10021 USA
[10] Johns Hopkins Univ, Sch Med, Oncol Bioinformat Core, Baltimore, MD USA
[11] Russian Acad Sci, Vavilov Inst Gen Genet, Lab Syst Biol & Computat Genet, Moscow, Russia
[12] Johns Hopkins Univ, Sch Med, Sol Goldman Pancreat Canc Res Ctr, Baltimore, MD USA
[13] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
[14] Mem Sloan Kettering Canc Ctr, Ctr Mol Oncol, 1275 York Ave, New York, NY 10021 USA
关键词
IMMUNE CHECKPOINT BLOCKADE; LARGE GENE LISTS; PD-1; BLOCKADE; PANCREATIC-CANCER; LUNG-CANCER; MELANOMA; MUTATIONS; EVOLUTION; METASTASIS; EXPRESSION;
D O I
10.1158/1078-0432.CCR-17-0270
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To explore factors associated with response and resistance to anti-PD-1 therapy, we analyzed multiple disease sites at autopsy in a patient with widely metastatic melanoma who had a heterogeneous response. Materials and Methods: Twenty-six melanoma specimens (four premortem, 22 postmortem) were subjected to whole exome sequencing. Candidate immunologic markers and gene expression were assessed in 10 cutaneous metastases showing response or progression during therapy. Results: The melanoma was driven by biallelic inactivation of NF1. All lesions had highly concordant mutational profiles and copy number alterations, indicating linear clonal evolution. Expression of candidate immunologic markers was similar in responding and progressing lesions. However, progressing cutaneous metastases were associated with overexpression of genes associated with extracellular matrix and neutrophil function. Conclusions: Although mutational and immunologic differences have been proposed as the primary determinants of heterogeneous response/resistance to targeted therapies and immunotherapies, respectively, differential lesional gene expression profiles may also dictate anti-PD-1 outcomes. (C) 2017 AACR. See related commentary by Wilmott et al., p. 2921
引用
收藏
页码:3168 / 3180
页数:13
相关论文
共 47 条
[31]  
Seftor REB, 2002, MOL CANCER THER, V1, P1173
[32]   FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing [J].
Shen, Ronglai ;
Seshan, Venkatraman E. .
NUCLEIC ACIDS RESEARCH, 2016, 44 (16)
[33]   Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma [J].
Snyder, Alexandra ;
Makarov, Vladimir ;
Merghoub, Taha ;
Yuan, Jianda ;
Zaretsky, Jesse M. ;
Desrichard, Alexis ;
Walsh, Logan A. ;
Postow, Michael A. ;
Wong, Phillip ;
Ho, Teresa S. ;
Hollmann, Travis J. ;
Bruggeman, Cameron ;
Kannan, Kasthuri ;
Li, Yanyun ;
Elipenahli, Ceyhan ;
Liu, Cailian ;
Harbison, Christopher T. ;
Wang, Lisu ;
Ribas, Antoni ;
Wolchok, Jedd D. ;
Chan, Timothy A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (23) :2189-2199
[34]   Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity [J].
Spranger, Stefani ;
Bao, Riyue ;
Gajewski, Thomas F. .
NATURE, 2015, 523 (7559) :231-U261
[35]   Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade [J].
Taube, Janis M. ;
Young, Geoffrey D. ;
McMiller, Tracee L. ;
Chen, Shuming ;
Salas, January T. ;
Pritchard, Theresa S. ;
Xu, Haiying ;
Meeker, Alan K. ;
Fan, Jinshui ;
Cheadle, Chris ;
Berger, Alan E. ;
Pardoll, Drew M. ;
Topalian, Suzanne L. .
CLINICAL CANCER RESEARCH, 2015, 21 (17) :3969-3976
[36]   Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy [J].
Taube, Janis M. ;
Klein, Alison ;
Brahmer, Julie R. ;
Xu, Haiying ;
Pan, Xiaoyu ;
Kim, Jung H. ;
Chen, Lieping ;
Pardoll, Drew M. ;
Topalian, Suzanne L. ;
Anders, Robert A. .
CLINICAL CANCER RESEARCH, 2014, 20 (19) :5064-5074
[37]   Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape [J].
Taube, Janis M. ;
Anders, Robert A. ;
Young, Geoffrey D. ;
Xu, Haiying ;
Sharma, Rajni ;
McMiller, Tracee L. ;
Chen, Shuming ;
Klein, Alison P. ;
Pardoll, Drew M. ;
Topalian, Suzanne L. ;
Chen, Lieping .
SCIENCE TRANSLATIONAL MEDICINE, 2012, 4 (127)
[38]  
TOPALIAN SL, 1989, J IMMUNOL, V142, P3714
[39]   Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy [J].
Topalian, Suzanne L. ;
Taube, Janis M. ;
Anders, Robert A. ;
Pardoll, Drew M. .
NATURE REVIEWS CANCER, 2016, 16 (05) :275-287
[40]   Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy [J].
Topalian, Suzanne L. ;
Drake, Charles G. ;
Pardoll, Drew M. .
CANCER CELL, 2015, 27 (04) :450-461